Atea Pharma Hits Development Milestone for Covid-19 Treatment
June 16 2021 - 7:53AM
Dow Jones News
By Chris Wack
Atea Pharmaceuticals Inc. said it has achieved a milestone
associated with the development of AT-527, and expects to receive a
related payment under its license agreement with Roche of $50
million.
Under the license agreement, Roche and Atea are jointly
developing AT-527 for the treatment of Covid-19.
AT-527 is an orally administered, direct-acting antiviral
developmental agent derived from Atea's purine nucleotide pro-drug
platform, and it is in Phase 3 development for the treatment of
Covid-19, Atea said.
Atea retains rights to commercialize AT-527 in the U.S., and
Roche has the exclusive right to commercialize AT-527 outside the
U.S.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 16, 2021 07:41 ET (11:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024